Prosecution Costs Sample Clauses
The Prosecution Costs clause defines which party is responsible for covering the expenses associated with pursuing legal action, such as enforcing intellectual property rights or defending against infringement. Typically, this clause outlines whether costs like attorney fees, court fees, and other litigation expenses are borne by the party initiating the action or shared between parties. Its core function is to allocate financial responsibility for legal proceedings, thereby clarifying expectations and reducing disputes over who pays for prosecution-related costs.
Prosecution Costs. Licensee shall pay future costs of the prosecution of the patent applications pending as set forth in ARTICLE I, Paragraph 2, which are reasonably necessary to secure the patent. Furthermore, Licensee will pay for the costs of filling, prosecuting and maintaining foreign counterpart applications to such pending patent applications, such foreign applications to be filed within ten (10) months prior to the filling date of the corresponding United States patent application.
Prosecution Costs. During the Term of this Agreement, all costs associated with filing, prosecuting, issuing and maintaining (i) the Raf/[*] Patents, the Sunesis Collaboration Patents, the Licensed Pre-Existing Patents and patent applications and patents within the Sunesis Core Technology shall be borne by Sunesis; and (ii) the Biogen Idec Collaboration Patents and Joint Collaboration Patents shall be borne by Biogen Idec.
Prosecution Costs. All reasonable Out-of-Pocket costs of the Parties or its Affiliates related to the prosecution of the Joint Collaboration Patent Rights (“Shared Prosecution Costs”), will be shared by the Parties in accordance with Article 12 (Payments); [***]. Otherwise, [***].
Prosecution Costs. CSMC will prepare, file, prosecute and maintain the Patent Rights during the Option Period and Licensee shall reimburse CSMC for the costs and expenses, including reasonable attorneys’ fees, filing fees and translation fees actually incurred by CSMC (including but not limited to any costs and expenses related to foreign filings) in the prosecution of the Patent Rights (“Prosecution Costs”) during the Option Period. Licensee shall reimburse CSMC within thirty (30) days of receiving an invoice from CSMC for such Prosecution Costs. Further, the Exclusive License shall provide that Licensee will reimburse CSMC for Prosecution Costs actually incurred by CSMC in the prosecution of any Patent Rights prior to the Option Period. The Exclusive License shall provide that Licensee shall control patent prosecution and be responsible for all Prosecution Costs related to the Patent Rights following its exercise of the Option.
Prosecution Costs costs of the filing for, prosecution and maintenance of Sole Patent Rights or Joint Patent Rights under Sections 10.2.1 and 10.2.2 above, in each case incurred after the Effective Date, shall be treated as follows:
Prosecution Costs. Except as otherwise expressly provided hereunder, Roche shall bear all out-of-pocket costs and expenses of Handling PTC Patent Rights, Roche Patent Rights and Joint Patent Rights, and shall reimburse PTC for any such costs PTC incurs in connection therewith within [**] days after receipt of an invoice from PTC therefor.
Prosecution Costs reasonable and, costs and expenses incurred, with the Insurer’s prior written consent, by an Insured Person, to bring legal proceedings for a declaration and/or an injunction. Prosecution Costs shall not include the remuneration of any Insured Person, costs of their time or any other costs or overheads of any Company.
Prosecution Costs. Memory shall be solely responsible for payment of the reasonable costs to Handle the Memory Patent Rights, except as otherwise provided in Section 13.2 above.
Prosecution Costs. [* * *].
Prosecution Costs. All costs incurred by DOT-1 after the Effective Date associated with filing, prosecuting, issuing, maintaining, and extending the Patent Rights described in Section 9.2.2 shall, as between the Parties, be borne by DOT-1.